Gilead gains late-stage cancer candidate through $465mm purchase of YM BioSciences
Gilead Sciences Inc. has offered $2.95 per share (an 81% premium), or about $465mm, to purchase cancer and inflammatory disease company YM BioSciences Inc. The Canadian biopharma reported $1mm in revenues for 2012, and had $125mm in cash and cash equivalents as of September 30, 2012.
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com